Vertex, Bristol to conduct midstage trials of hep C combo therapy

04/8/2013 | Genetic Engineering & Biotechnology News

Vertex Pharmaceuticals and Bristol-Myers Squibb signed a non-exclusive deal to initiate two midstage trials of a once-a-day combination therapy for hepatitis C. The trials will test the safety, tolerability, pharmacokinetics and viral cure rates of Vertex's VX-135, a nucleotide analogue hepatitis C virus polymerase inhibitor, in combination with Bristol's daclatasvir, an experimental NS5A replication complex inhibitor.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY